New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
07:03 EDTIDRAIdera Pharmaceuticals reports Q1 EPS (12c), two estimates (8c)
Reports Q1 revenue $3,000, two estimates $3,000. The company anticipates enrolling up to approximately 30 patients in a Phase 1/2 trial of IMO-8400 in patients with trial DLBCL who harbor the MYD88 L265P mutation and have relapsed or were refractory to prior therapy. The company expects to initiate patient treatment in the second half of 2014. A Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström’s macroglobulinemia, who have relapsed or were refractory to prior therapy, is ongoing. This trial is designed to evaluate safety, tolerability and clinical activity of escalating IMO-8400 dose levels. The Company anticipates enrolling up to approximately 30 patients in this trial. In March, the company announced positive top-line data from a randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis. The trial met the primary objective of demonstrating safety and tolerability, as well as a secondary objective of clinical activity of IMO-8400. The company intends to submit the full data set, including data from an additional higher dose cohort, for presentation at a medical meeting in 2014.
News For IDRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 24, 2015
07:31 EDTIDRARBC Capital to hold a conference
Subscribe for More Information
February 17, 2015
09:42 EDTIDRABaker Brothers Advisors buy 5.33M shares of Idera Pharmaceuticals
A filing by Idera Pharmaceuticals director Julian Baker showed that his Baker Bros. Advisors purchased about 5.33M shares of the company's stock in transactions on February 13 at an average price of $3.75 per shares. Idera Pharmaceutical shares are up 6.5% to $4.37 in early trading.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use